Buprenorphine Supply,Access,and Quality: Where We Have Come and the Path Forward

Abstract

Buprenorphine is a form of opioid agonist treatment that has been demonstrated to be an effective medication for opioid addiction. It is available in different formulations and marketed under various trade names, including commonly as a buprenorphine/naloxone combination. This paper provides an overview of existing literature on the supply of buprenorphine treatment, the ability of people to access treatment with buprenorphine, and the quality of treatment received. We argue that better data for each of these aspects of treatment could inform policy to expand effective treatment with buprenorphine, and we suggest steps to obtain and act on such data.

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Drug Overdose Death Data, available at <https://www.cdc.gov/drugoverdose/data/statedeaths.html> (last visited Jan. 24, 2018).

Hedegaard ,

Warner , and

A. M.

Miniño , Drug Overdose Deaths in the United States, 1999–2016, NCHS Data Brief, no 294 (Hyattsville, MD: National Center for Health Statistics, 2017).

R. P.

Mattick ,

Breen ,

Kimber , and

Davoli , “Buprenorphine Maintenance Versus Placebo or Methadone Maintenance for Opioid Dependence,” Cochrane Database of Systematic Reviews, no. 2 (2014): CD002207.

N.D.

Volkow ,

T.R.

Frieden ,

P.S.

Hyde , and

S.S.

Cha , Perspective, “Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic,” New England Journal of Medicine 370, no. 22 (2014): 2063-2066.

21 U.S.C. § 823 (2018).

Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Methadone, available at <https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone> (last visited Feb. 21, 2018).

See supra note 5.

42 C.F.R. § 8.610 (2018).

21 U.S.C. § 823 (2018).

10.

C. M.

Jones ,

Campopiano ,

Baldwin , and

McCance-Katz , “National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment,” American Journal of Public Health 105, no. 8 (2015): 55-63.

11.

R. A.

Rosenblatt ,

C. H.

Andrilla ,

Catlin , and

E. H.

Larson , “Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder,” Annals of Family Medicine 13, no. 1 (2015): 23-26.

12.

Id.;

S. C.

Sigmon

, “Access to Treatment for Opioid Dependence in Rural America: Challenges and Future Directions,” JAMA Psychiatry 71, no. 4 (2014): 359-360.

13.

A. S.

Huhn and

K. E.

Dunn , “Why Aren’t Physicians Prescribing More Buprenorphine?” Journal of Substance Abuse Treatment 78 (2017): 1-7.

14.

Id .

15.

Turner ,

S. P.

Kruszewski , and

G. C.

Alexander , “Trends in the Use of Buprenorphine by Office-Based Physicians in the United States, 2003-2013,” American Journal on Addictions 24, no. 1 (2015): 24-29.

16.

A. W.

Dick ,

R. L.

Pacula ,

A. J.

Gordon ,

Sorbero ,

R. M.

Burns ,

Leslie , and

B. D.

Stein , “Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002-11,” Health Affairs 34, no. 6 (2015): 1028-1034.

17.

H. K.

Knudsen ,

J. R.

Havens ,

M. R.

Lofwall ,

J. L.

Studts , and

S. L.

Walsh , “Buprenorphine Physician Supply: Relationship with State-Level Prescription Opioid Mortality,” Drug and Alcohol Dependence 173, Supplement 1 (2017): S55-S64.

18.

B. D.

Stein ,

R. L.

Pacula ,

A. J.

Gordon ,

R. M.

Burns ,

D. L.

Leslie ,

M. J.

Sorbero ,

Bauhoff ,

T. W.

Mandell , and

A. W.

Dick , “Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties,” Milbank Quarterly 93, no. 3 (2015): 561-583.

19.

Id .

20.

Id .

21.

B. D.

Stein ,

Sorbero ,

A. W.

Dick ,

R. L.

Pacula ,

R. M.

Burns , and

A. J.

Gordon , “Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment,” JAMA 316, no. 11 (2016): 1211-1212; C. P. Thomas, E. Doyle, P. W. Kreiner, C. M. Jones, J. Dubenitz, A. Horan, and B. D. Stein, “Prescribing Patterns of Buprenorphine Waivered Physicians,” Drug and Alcohol Dependence 181 (2017): 213-218.

22.

Polydorou ,

E. W.

Gunderson , and

F. R.

Levin , “Training Physicians to Treat Substance Use Disorders,” Current Psychiatry Reports 10, no. 5 (2008): 399-404.

23.

E. W.

Gunderson ,

D. A.

Fiellin ,

F. R.

Levin ,

L. E.

Sullivan , and

H. D.

Kleber , “Evaluation of a Combined Online and in Person Training in the Use of Buprenorphine,” Substance Abuse 27, no. 3 (2006): 39-45; See also D. T. Barry, K. S. Irwin, E. S. Jones, W. C. Becker, J. M. Tetrault, L. E. Sullivan, H. Hansen, et al., “Integrating Buprenorphine Treatment into Office-Based Practice: A Qualitative Study,” Journal of General Internal Medicine 24, no. 2 (2009): 218-225.

24.

F. R.

Levin ,

Bisaga ,

M. A.

Sullivan ,

A. R.

Williams , and

Cates-Wessel , “A Review of a National Training Initiative to Increase Provider Use of MAT to Address the Opioid Epidemic,” American Journal on Addictions 25, no. 8 (2016): 603-609; J. E. Egan, P. Casadonte, T. Gartenmann, J. Martin, E. F. McCance-Katz, J. Netherland, J. A. Renner, L. Weiss, A.J. Saxon, and D. A. Fiellin, “The Physician Clinical Support System-Buprenorphine (PCSS-B): A Novel Project to Expand/Improve Buprenorphine Treatment,” Journal of General Internal Medicine 25, no. 9 (2010): 936-941.

25.

T. V.

Parran ,

J. Z.

Muller ,

Chernyak ,

Adelman ,

C. M.

Delos Reyes ,

Rowland , and

Kolganov , “Access to and Payment for Office-Based Buprenorphine Treatment in Ohio,” Substance Abuse: Research and Treatment 11 (2017): 1-6.

26.

H. B.

Hansen ,

C. E.

Siegel ,

B. G.

Case ,

D. N.

Bertollo ,

DiRocco , and

Galanter , “Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic and Income Characteristics of Residential Social Areas in New York City,” Journal of Behavioral Health Services & Research 40, no. 3 (2013): 367-377.

27.

Wen ,

J. M.

Hockenberry ,

T. F.

Borders , and

B. G.

Druss , “Impact of Medicaid Expansion on Medicaid-Covered Utilization of Buprenorphine for Opioid Use Disorder Treatment,” Medical Care 55, no. 4 (2017): 336-341; J.C. Maclean and B. Saloner, “The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act,” NBER Working Paper 23342 (Cambridge, MA: National Bureau of Economic Research, 2017).

28.

H. K.

Knudsen

, “The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis,” Journal of Studies on Alcohol and Drugs 76, no. 4 (2015): 644-654.

29.

Kermack ,

Flannery ,

Tofighi ,

McNeely , and

J. D.

Lee , “Buprenorphine Prescribing Practice Trends and Attitudes among New York Providers,” Journal of Substance Abuse Treatment 74 (2017): 1-6.

30.

American Society of Addiction Medicine, Advancing Access to Addiction Medications: Implications for Opioid Addiction Treatment (2013).

31.

R. M.

Burns ,

R. L.

Pacula ,

Bauhoff ,

A. J.

Gordon ,

Hendrikson ,

D. L.

Leslie , and

B. D.

Stein , “Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013,” Substance Abuse 37, no. 1 (2016): 63-69.

32.

Kaiser Family Foundation, States Reporting Managed Care Pharmacy Uniform Preferred Drug List Requirements, available at <https://www.kff.org/medicaid/state-indicator/states-reporting-managed-care-pharmacy-uniform-preferred-drug-list-pdl-requirements> (last visited Jan. 24, 2018).

33.

See American Society of Addiction Medicine, supra note 30.

34.

R. E.

Clark ,

J. D.

Baxter ,

B. A.

Barton ,

Aweh ,

O’Connell , and

W. H.

Fisher , “The Impact of Prior Authorization on Buprenorphine Dose, Relapse Rates, and Cost for Massachusetts Medicaid Beneficiaries with Opioid Dependence,” Health Services Research 49, no. 6 (2014): 1964-1979.

35.

Harper

, “Indiana Just Made Getting Addiction Treatment A Little Bit Easier,” WYFI Indianapolis, November 17, 2017, available at <https://www.wfyi.org/news/articles/indiana-just-made-getting-addiction-treatment-a-little-bit-easier> (last visited Jan. 24, 2018).

36.

Luthra

, “Another Big Health Insurer Loosens Rules for Addiction Treatment,” NPR News, February 15, 2017, available at <https://www.npr.org/sections/health-shots/2017/02/15/515239382/another-big-health-insurer-loosens-rules-for-covering-addiction-treatment> (last visited Jan. 24, 2018).

37.

S. E.

Wakeman

, “Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy,” AMA Journal of Ethics 19, no. 9 (2017): 922-930.

38.

Id .

39.

R. D.

Bruce and

R. A.

Schleifer , “Ethical and Human Rights Imperatives to Ensure Medication-Assisted Treatment for Opioid Dependence in Prisons and Pre-Trial Detention,” International Journal of Drug Policy 19, no. 1 (2008): 17-23.

40.

Krawczyk ,

C. E.

Picher ,

K. A.

Feder , and

Saloner , “Only One in Twenty Justice-Referred Adults in Specialty Treatment for Opioid Use Receive Methadone or Buprenorphine,” Health Affairs (Millwood), 36, no. 12 (2017): 2046-2053.

41.

Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, Treatment Improvement Protocol (TIP) Series, No. 40 (Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004); K. Kampman and M. Jarvis, “American Society of Addiction Medicine (ASM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use,” Journal of Addiction Medicine 9, no. 5 (2015): 358-367.

42.

“Goals & Objectives,”

PCSS MAT Training, available at <https://pcssmat.org/about/goals-objectives/#develop> (last visited February 6, 2018).

43.

D. A.

Fiellin ,

P. G.

O’Connor ,

Chawarski , and

R. S.

Schottenfeld , “Processes of Care During a Randomized Trial of Office-Based Treatment of Opioid Dependence in Primary Care,” American Journal on Addictions 13, Supplement 1 (2004): S67-S78.

44.

W. F.

Gellad ,

Zhao ,

C. T.

Thorpe , et al., “Overlapping Buprenorphine, Opioid, and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in VA and Medicare Part D,” Substance Abuse 38, no. 1 (2017): 22-25; B. Mund and K. Stith, “Buprenorphine MAT as an Imperfect Fix,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 279-291.

45.

A. J.

Gordon ,

W. H.

Lo-Ciganic ,

Cochran ,

W. F.

Gellad ,

Cathers ,

Kelley , and

J. M.

Donohue , “Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program,” Journal of Addiction Medicine 9, no. 6 (2015): 470-477

46.

Gordon ,

W. H.

Lo-Ciganic ,

Cochran ,

W. F.

Gellad ,

Cathers , and

J. M.

Donohue , “Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow,” Journal of Addiction Medicine 10, no. 3 (2016): 210-211.

47.

R. C.

Sherrick

, “Measuring Quality of Buprenorphine Care,” Journal of Addiction Medicine 10, no. 3 (2016): 209-210.

48.

Butler ,

Becker , and

Humphries , “Big Data and the Opioid Crisis: Balancing Patient Privacy with Public Health,” Journal of Law, Medicine & Ethics 46, no. 2 (2018): 440-453.

49.

Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, “HHS Makes Effort to Increase Access to Treatment of Opioid Use Disorder,” Buprenorphine Prescriber News (Winter 2017), available at <http://www.dsgonline.com/DataWaiver/enews/2017/2017_11_28/dw_enews_web.html> (last visited January 24, 2018).

50.

Vestal

, “Nurse Licensing Laws Block Treatment for Opioid Addiction,” The Pew Charitable Trusts, Stateline, April 21, 2017, available at <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/04/21/nurse-licensing-laws-block-treatment-for-opioid-addiction> (last visited February 3, 2018).

51.

Legal Action Center, Legality of Denying Access to Medication Assisted Treatment in the Criminal Justice System, December 1, 2011; National Association of Drug Court Professionals, Adult Drug Court Best Practice Standards Volume I, (2013); Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Einstein Expert Panel: Medication-Assisted Treatment and the Criminal Justice System, Report of Proceedings, September 10, 2013.

52.

J. K.

Eibl ,

Gauthier ,

Pellegrini ,

Daiter ,

Varenbut ,

J. C.

Hogenbirk , and

D. C.

Marsh , “The Effectiveness of Tele-medicine-Delivered Opioid Agonist Therapy in a Supervised Clinical Setting,” Drug and Alcohol Dependence 176 (2017): 133-138.

53.

Suzuki ,

Zinser ,

Klaiber ,

Hannon ,

Grassi ,

Spinosa ,

Ramirez ,

Issa , and

S. P.

Chin Feman , “Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment with Buprenorphine: A Pilot Study,” Substance Abuse 36, no. 2 (2015): 166-169.

54.

A. D.

Fox ,

Chamberlain ,

N. L.

Sohler ,

Frost , and

C. O.

Cunningham , “Illicit Buprenorphine Use, Interest in and Access to Buprenorphine Treatment among Syringe Exchange Participants,” Journal of Substance Abuse Treat 48, no. 1 (2015): 112-116; M. R. Lofwall, and S. L. Walsh, “A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences from around the World,” Journal of Addiction Medicine 8, no. 5 (2014): 315-326.

55.

Olsen and

J. M.

Sharfstein , “Confronting the Stigma of Opioid Use Disorder — and Its Treatment,” JAMA 311, no. 14 (2014): 1393-1394.